Magnendo Corp. has raised $18.0M in a Series A round backed by Penumbra, a bet on robotic precision in one of medicine’s most time-critical fields. The company is working to change how stroke and brain aneurysm treatments are delivered, aiming to make access faster, safer, and simpler through robotics.
The funding arrives as interventional neurology increasingly looks to automation to reduce procedure times and human error. With Penumbra-a player already familiar with the vascular space-stepping in as the sole investor, Magnendo gains both capital and a strategic ally. The company hasn’t detailed specific next steps, but the focus is clear: bring robotic tools to the front lines of acute brain care.
